Endocyte has announced results from its Phase 2 clinical study of EC145 in patients with advanced non-small cell lung cancer (NSCLC). The primary objective of this trial was to determine the percentage of patients who completed four months of therapy without disease progression while treated with EC145. The trial showed that at least 30 percent of all patients treated with EC145 achieved this threshold. EC20, a targeted molecular diagnostic imaging agent, was used to identify patients whose tumors expressed the folate receptor, the target of EC145. An analysis of EC20 positive patients receiving EC145 as third or fourth line therapy indicated a clinical benefit rate of 45 percent.
The EC145 molecule uses folate to target the folate receptors found in high concentrations on the surface of tumors, including NSCLC, ovarian, renal and many other cancers. By binding directly to cells that over-express folate receptors, EC145 delivers the anticancer agent directly to cancer cells while avoiding normal tissue.
For more information call (765) 463-7175 or visit www.endocyte.com/pipeline.html.